Cargando…

Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes

BACKGROUND: Onchocerciasis is targeted for elimination in Africa through annual or biannual ivermectin mass drug administration (MDA). An immunodiagnostic test, based on the detection of human IgG4 antibodies in the blood to the Onchocerca volvulus-specific antigen Ov16, is one of the recommended to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lont, Yvonne L., Coffeng, Luc E., de Vlas, Sake J., Golden, Allison, de los Santos, Tala, Domingo, Gonzalo J., Stolk, Wilma A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289624/ https://www.ncbi.nlm.nih.gov/pubmed/28114304 http://dx.doi.org/10.1371/journal.pntd.0005314

Ejemplares similares

Predictive Value of Ov16 Antibody Prevalence in Different Subpopulations for Elimination of African Onchocerciasis
por: Coffeng, Luc E, et al.
Publicado: (2019)

Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis
por: Golden, Allison, et al.
Publicado: (2016)

Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis
por: Stolk, Wilma A., et al.
Publicado: (2015)

Elimination of African Onchocerciasis: Modeling the Impact of Increasing the Frequency of Ivermectin Mass Treatment
por: Coffeng, Luc E., et al.
Publicado: (2014)

The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages
por: de Vos, Anneke S., et al.
Publicado: (2021)

Structural Uncertainty in Onchocerciasis Transmission Models Influences the Estimation of Elimination Thresholds and Selection of Age Groups for Seromonitoring
por: Hamley, Jonathan I D, et al.
Publicado: (2020)

The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis
por: de Vos, Anneke S., et al.
Publicado: (2018)

Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results
por: Tekle, Afework H., et al.
Publicado: (2016)

Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling
por: Stolk, Wilma A, et al.
Publicado: (2006)

Scaling-Down Mass Ivermectin Treatment for Onchocerciasis Elimination: Modeling the Impact of the Geographical Unit for Decision Making
por: Stolk, Wilma A, et al.
Publicado: (2021)

African Programme for Onchocerciasis Control 1995–2015: Model-Estimated Health Impact and Cost
por: Coffeng, Luc E., et al.
Publicado: (2013)

How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

Burden of onchocerciasis-associated epilepsy: first estimates and research priorities
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2018)

What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
por: Hamley, Jonathan I D, et al.
Publicado: (2021)

African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases
por: Krotneva, Stanimira P., et al.
Publicado: (2015)

Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal
por: Dieye, Yakou, et al.
Publicado: (2017)

Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening
por: Dusabimana, Alfred, et al.
Publicado: (2022)

African Programme for Onchocerciasis Control 1995–2015: Updated Health Impact Estimates Based on New Disability Weights
por: Coffeng, Luc E., et al.
Publicado: (2014)

Feasibility of Onchocerciasis Elimination Using a “Test-and-not-treat” Strategy in Loa loa Co-endemic Areas
por: Blok, David J, et al.
Publicado: (2020)

Onchocerciasis: The Pre-control Association between Prevalence of Palpable Nodules and Skin Microfilariae
por: Coffeng, Luc E., et al.
Publicado: (2013)

How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control
por: Verver, Suzanne, et al.
Publicado: (2018)

Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2020)

Changes in Onchocerciasis Ov16 IgG4 Rapid Diagnostic Test Results Over One-Month Follow-up: Lessons for Reading Timeframe and Decision-Making
por: Nana-Djeunga, Hugues C., et al.
Publicado: (2022)

Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa
por: Kim, Young Eun, et al.
Publicado: (2017)

Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa
por: Stolk, Wilma A., et al.
Publicado: (2022)

Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. Pathogens 2022, 11, 281
por: Dusabimana, Alfred, et al.
Publicado: (2022)

Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions
por: Colebunders, Robert, et al.
Publicado: (2019)

Diagnostics for onchocerciasis in the era of elimination
por: Unnasch, Thomas R, et al.
Publicado: (2018)

Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
por: Shintouo, Cabirou Mounchili, et al.
Publicado: (2021)

Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies
por: Prada, Joaquín M, et al.
Publicado: (2021)

Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
por: Stolk, Wilma A., et al.
Publicado: (2013)

Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India
por: Le Rutte, Epke A, et al.
Publicado: (2021)

Antibody and Antigen Prevalence as Indicators of Ongoing Transmission or Elimination of Visceral Leishmaniasis: A Modeling Study
por: Coffeng, Luc E, et al.
Publicado: (2021)

Concordance between Ov16 rapid diagnostic test(RDT) and Ov16 enzyme-linked immunosorbent assay (ELISA) for the diagnosis of onchocerciasis in areas of contrasting endemicity in cameroon
por: Ekanya, Relindis, et al.
Publicado: (2023)

Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions
por: Biamonte, Marco A., et al.
Publicado: (2022)

Outstanding insecurities concerning the use of an Ov16-based ELISA in the Amazonia onchocerciasis focus
por: Luz, Sérgio Luiz Bessa, et al.
Publicado: (2014)

Navigating the way to onchocerciasis elimination: the feasibility and affordability of Onchocerciasis Elimination Mapping
por: Hamill, Louise, et al.
Publicado: (2022)

Quantifying the value of surveillance data for improving model predictions of lymphatic filariasis elimination
por: Michael, Edwin, et al.
Publicado: (2018)

Correction: Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions
por: Biamonte, Marco A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0hajhdr6f9msf8783tck368mq7